ProCE Banner Activity

CE / CME

Key Considerations for Using JAK Inhibitors for Alopecia Areata

Clinical Thought

The treatment landscape for alopecia areata (AA) is shifting with the recent FDA approval of a JAK inhibitor and a robust development pipeline. In this commentary, we share our thoughts on the best strategies for classifying AA and key points for integrating JAK inhibitors into AA treatment plans.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 10, 2023

Expiration: October 09, 2024

Share

Faculty

Brittany Craiglow

Brittany Craiglow, MD

Associate Adjunct Professor
Department of Dermatology
Yale School of Medicine
New Haven, Connecticut

Maryanne Makredes Senna

Maryanne Makredes Senna, MD, FAAD

Assistant Professor of Dermatology 
Harvard Medical School 
Boston, Massachusetts 
Director, Lahey Hair Loss Center of Excellence
Lahey Hospital and Medical Center 
Burlington, Massachusetts

Provided by

Provided by Clinical Care Options, LLC in partnership with the National Alopecia Areata Foundation

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

National Alopecia Areata Foundation

ProCE Banner

Target Audience

The intended target audience for this program is US dermatologists and NP/PAs who treat patients with AA.

Program Learning Goal

The goal of this program is for learners to demonstrate and improve their application of knowledge, clinical performance, and confidence in making treatment decisions to optimize the treatment of patients with AA.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate an accurate diagnosis and classification of AA based on multiple disease and patient factors

  • Detail factors that may predict a patient’s positive or negative response to JAK inhibitor therapy for AA

  • Evaluate patients with AA for treatment candidacy with JAK inhibitor therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Brittany Craiglow, MD

Associate Adjunct Professor
Department of Dermatology
Yale School of Medicine
New Haven, Connecticut

Brittany Craiglow, MD: consultant/advisor/speaker: AbbVie, Concert Pharmaceuticals, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme.

Maryanne Makredes Senna, MD, FAAD

Assistant Professor of Dermatology 
Harvard Medical School 
Boston, Massachusetts 
Director, Lahey Hair Loss Center of Excellence
Lahey Hospital and Medical Center 
Burlington, Massachusetts

Maryanne Makredes Senna, MD, FAAD: consultant/advisor/speaker: AbbVie, Eli Lilly, Kintor, L'Oréal, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC and the National Alopecia Areata Foundation have no relevant financial relationships to disclose, except Douglas DiRuggiero, DMSc, MHS, PA-C as noted below:

Douglas DiRuggiero, DMSc, MHS, PA-C: consultant/advisor/speaker: Abbvie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, EPI Health, Incyte, Lilly, Novartis, Sanofi/Regeneron, Sun Pharmaceuticals, UCB.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 10, 2023, through October 09, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Alopecia Areata Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Physician Associates Continuing Medical Education
Joint AccreditationClinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until  October 09, 2024. PAs should only claim credit commensurate with the extent of their participation.